Success Metrics

Active Trials
1(50%)

Phase Distribution

Ph early_phase_1
1
50%
Ph phase_1
1
50%

Phase Distribution

2

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Early Phase 1First-in-human
1(50.0%)
Phase 1Safety & dosage
1(50.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

2

all time

Status Distribution
Active(2)

Detailed Status

Recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
1
Success Rate
N/A
Most Advanced
Early Phase 1

Trials by Phase

Early Phase 11 (50.0%)
Phase 11 (50.0%)

Trials by Status

recruiting150%
not_yet_recruiting150%

Recent Activity

1 active trials
Showing 2 of 2
not_yet_recruitingearly_phase_1

Phase 0/2 PD-Trigger Study of BGB-58067 in Newly Diagnosed Glioblastoma Patients With MTAP-Deleted Tumors

NCT07485049
recruitingphase_1

An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors

NCT06589596

Clinical Trials (2)

Showing 2 of 2 trials
NCT07485049Early Phase 1

Phase 0/2 PD-Trigger Study of BGB-58067 in Newly Diagnosed Glioblastoma Patients With MTAP-Deleted Tumors

Not Yet Recruiting
NCT06589596Phase 1

An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors

Recruiting

All 2 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
2